Methadone (Dolophine®), Serum
Methadone (Dolophine®), Serum
    
Number
007781
CPT
83840
Synonyms
Dolophine®
Specimen
Serum or plasma
Volume
3 mL
Minimum Volume
1.1 mL
Container
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube
Collection
Transfer separated serum or plasma to a plastic transport tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Storage Instructions
Refrigerate
Causes for Rejection
Gel-barrier tube
Reference Interval
Therapeutic: 100-400 ng/mL
Critical Values
Potentially toxic: >2000 ng/mL
Use
For therapeutic monitoring only. Methadone possesses many of the pharmacologic properties of morphine and is approximately equipotent as an analgesic when administered parenterally. Unlike morphine, however, methadone produces marked sedative effects with repeated administration as a result of drug accumulation. This undesirable property restricted clinical usage of the drug until 1965 when Dole and Nyswander began narcotic maintenance treatment of former heroin addicts using large daily oral doses of dl-methadone. Whereas maintenance patients may receive as much as 180 mg of the drug daily, doses ≤50 mg have been known to prove fatal to nontolerant adults. The pharmacologic activity is due almost entirely to the l-isomer. The d-methadone isomer does have analgesic properties in large doses and this may be due to conversion to minor amounts of alpha-l-methadone and alpha-l-normethadol, both of which are potent analgesics.
Methodology
Mass spectrometry (MS)
Additional Information
Methadone can be detected in blood 15-45 minutes after oral administration, with peak levels occurring at 2.5-4 hours. The elimination of half-life has a mean value of approximately 22 hours (range 5-130 hours). Due to interindividual variation of P450 enzyme systems, up to a 17-fold variation in methadone blood concentrations can be found in patients given the same dose.1
Footnotes
  1. Eap CB, Buclin T, and Baumann P, “Interindividual Variability of the Clinical Pharmacokinetics of Methadone: Implications for the Treatment of Opioid Dependence,” Clin Pharmacokinet, 2002, 41(14):1153-93
References

Baselt RC and Cravey RH, Disposition of Toxic Drugs and Chemicals in Man, 4th ed, Foster City, CA: Chemical Toxicology Institute, 1995.


Copyright © 2007 by Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved